Colorado clarifies who their Upper Payment Limit rule applies to. Maryland picks six drugs to conduct cost reviews for and requests information from the public in an effort to produce something by year end. Oregon pauses affordability reviews for 2024 while it gathers feedback from stakeholders. Washington considers the eligibility criteria for drugs to be reviewed, looking to states like Colorado for guidance.